RxDoctor Payments Data

Gregory Everett, OD

Optometrist · Knoxville, TNNPI 1053675637

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 43 payments — averaging $36.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$418
  • Bausch & Lomb Americas Inc.$330
  • Alcon$221
  • Coopervision Inc.$160
  • Sun Pharmaceutical Industries Inc.$144
  • AbbVie$78
  • plus $216 from 6 others

What the payments were for

  • Food & beverage$1,567100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 70th percentile of 1,122 optometrist providers in Tennessee.

See all optometrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$108,232
Medicare patients
546
Services billed
1,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine15$18,523
LumiganBimatoprost32$13,750
XiidraLifitegrast14$12,783
CombiganBrimonidine Tartrate/Timolol21$10,312
VyzultaLatanoprostene Bunod11$3,951
Latanoprost201$2,278
Travoprost17$2,005
Timolol Maleate39$1,945
Brimonidine Tartrate36$1,164
Prednisolone Acetate31$1,142
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat68$1,109
Doxycycline Hyclate14$1,009
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol12$962
Doxycycline Monohydrate12$684
MoxifloxacinMoxifloxacin Hcl31$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$78$42,58568 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$330$16,73325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,122 optometrist providers in Tennessee.

Other optometrist in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →